All Stories

  1. Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis

    Article • Patient Preference and Adherence, March 2015, Taylor & Francis

    Chakkarin Burudpakdee

  2. Impact of Patient Programs On Adherence In Inflammation and Immunology: A Global Systematic Review and Meta-Analysis of Published Evidence

    Article • Value in Health, November 2014, Elsevier

    Chakkarin Burudpakdee

  3. A Guideline-Based Estimate of Health Care Resource Use and Cost of Metastatic Unresectable Osteosarcoma

    Article • Value in Health, November 2014, Elsevier

    Chakkarin Burudpakdee

  4. Comparison of Resource use and Health Care Costs in New Initiators of Long-Acting Injectable (Lai) and Oral Second Generation Antipsychotics

    Article • Value in Health, November 2014, Elsevier

    Chakkarin Burudpakdee

  5. Predictive Modeling to Assess Predictors of Treatment Success and Failure Among Combination Statin Therapy Patients

    Article • Value in Health, November 2014, Elsevier

    Chakkarin Burudpakdee

  6. The economic burden of psoriasis: a systematic literature review

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, July 2014, Taylor & Francis

    Chakkarin Burudpakdee

  7. Systematic Literature Review Of Compliance And Persistence Programs In Inflammation And Immunology

    Article • Value in Health, May 2014, Elsevier

    Chakkarin Burudpakdee

  8. Experiences and treatment patterns of hypogonadal men in a U.S. health system

    Article • International Journal of Clinical Practice, March 2014, Wiley

    Chakkarin Burudpakdee

  9. Systematic Literature Review of Economic Burden of Chronic Plaque Psoriasis

    Article • Value in Health, November 2013, Elsevier

    Chakkarin Burudpakdee

  10. PCN94 Feasibility of Efficiency Frontier Analysis (EFA) in Metastatic Breast Cancer (mBC) Treatments: A UK Perspective

    Article • Value in Health, November 2012, Elsevier

    Chakkarin Burudpakdee

  11. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany

    Article • Journal of Medical Economics, April 2012, Informa Healthcare

    Chakkarin Burudpakdee

  12. Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies

    Article • Journal of Medical Economics, January 2012, Informa Healthcare

    Chakkarin Burudpakdee

  13. PDB69 EXENATIDE (BID) AND LIRAGLUTIDE (QD) TREATMENT PATTERNS AMONG TYPE-2 DIABETES PATIENTS IN GERMANY

    Article • Value in Health, May 2011, Elsevier

    Chakkarin Burudpakdee

  14. PCN8 CLINICAL AND ECONOMIC BURDEN OF TOXICITIES ASSOCIATED WITH MONOCLONAL ANTIBODIES FOR METASTATIC COLORECTAL CANCER (MCRC)

    Article • Value in Health, November 2010, Elsevier

    Chakkarin Burudpakdee

  15. PAA1 SUB-ACUTE LACK OF ASTHMA CONTROL AND SUBSEQUENT ACUTE ASTHMA EXACERBATIONS: EVIDENCE FROM MANAGED CARE DATA

    Article • Value in Health, November 2007, Elsevier

    Chakkarin Burudpakdee